切换至 "中华医学电子期刊资源库"

中华神经创伤外科电子杂志 ›› 2015, Vol. 01 ›› Issue (04) : 237 -240. doi: 10.3877/cma.j.issn.2095-9141.2015.04.011

专题笔谈

人β-分泌酶与阿尔茨海默病
邓青山1, 马全红2, 徐如祥3,()   
  1. 1.637000 南充,川北医附院神经外科
    2.100700 北京,北京军区神经外科研究所
    3.215021 苏州,苏州大学神经科学研究所
  • 收稿日期:2015-02-28 出版日期:2015-08-15
  • 通信作者: 徐如祥

Human beta-secretase and Alzheimer's disease

Qingshang Deng1, Quanhong Ma2, Ruxiang Xu3,()   

  1. 1.Neurosurgery department of North Sichuan Medical College,Nanchong 637000 China
    2.Institute of Neuroscience,Soochow University,Suzhou 215021,China
    3.Institute of Neuroscience of Beijing Military Region,Beijing 100700,China
  • Received:2015-02-28 Published:2015-08-15
  • Corresponding author: Ruxiang Xu
引用本文:

邓青山, 马全红, 徐如祥. 人β-分泌酶与阿尔茨海默病[J]. 中华神经创伤外科电子杂志, 2015, 01(04): 237-240.

Qingshang Deng, Quanhong Ma, Ruxiang Xu. Human beta-secretase and Alzheimer's disease[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2015, 01(04): 237-240.

阿尔茨海默病(AD)是最常见的引起痴呆的神经退行性疾病,主要表现为进行性的认知功能障碍和行为能力障碍,其病理特征是神经细胞外不溶性淀粉样蛋白Aβ以及胞内由过磷酸化tau形成的纤维缠结.这种胞外聚合物主要由Aβ4两组成,它是由淀粉样前体蛋白APP依次经β分泌酶(β-secretase)和γ分泌酶(γ-secretase)剪切所产生的。沉积和细胞内过量的Tau蛋白磷酸化形成神经纤维缠结(NFTs),从而引起氧化应激和慢性炎症损伤,导致神经元丢失和突触功能障碍。基于对AD病理特征认识,以往将针对Aβ和NFTs的治疗作为AD治疗的主要方向,但是经过数十年的研究并未取得长足的进展。近年来,随着人们对β淀粉蛋白前体蛋白(APP)处理途径的认识不断深入,人们越来越重视APP降解产生Aβ的关键酶在AD发病中的作用。因此,本文就人β-分泌酶(β-secreatase,BACE1)的相关特性及在AD发病中的相关作用,以及在AD治疗中的研究进展做一综述。

Alzheimer's disease(AD)is the most common cause of dementia,neurodegenerative diseases,mainly characterized by progressive cognitive dysfunction and behavioral disabilities,its pathological characteristics are nerve cells outside insoluble amyloid beta and intracellular fiber which is formed by a phosphorylated tau tangles.This kind of extracellular oligomeric is mainly composed of Aβ,which is sequentially cleavaged the amyloid precursor protein APPbyβ-secretase andγ-secretase.Deposition and excessive tau protein phosphorylation in cells form a nerve fiber tangles(NFTs),so as to cause oxidative stress and chronic inflammation damage,which leads to neuronal loss and synaptic dysfunction.In the past,based on the understanding of AD pathology characteristics,we focused on Aβand NFTs as the main direction of AD treatment,but over decades of research we have not made great progress.In recent years,as the in-depth and developmental understanding of beta amyloid protein precursor protein(APP)processing,people pay more and more attention toβ-site APP-Cleaving Enzyme 1,a key enzyme in Alzheimer disease(AD).Therefore,theβ-secretase(BACE1)related features,functionsand the related treatment progressin Alzheimer diseasearereviewed in thispaper.

[32]
Vassar R,Kandalepas PC.The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease[J].Alzheimers Res Ther,2011,3(3):20.
[33]
Cai J,Qi X,Kociok N,et al.β-Secretase(BACE1)inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment[J].EMBO Mol Med,2012,4(9):980-991.
[34]
Chang WP,Huang X,Downs D,et al.Beta-secretaseinhibitor GRL-8234 rescues age-related cognitivedeclinein APP mice[J].FASEB J,2011,25(2):775-784.
[1]
Burns A,Iliffe S.Alzheimer's disease[J].BMJ,2009,5(2)338:b158.
[2]
Querfurth HW,LaFerla FM.Alzheimer's disease[J].N Engl J Med,2010,362(4):329-344.
[3]
Verri M,Pastoris O,Dossena M,et al.Mitochondrial alterations,oxidative stress and neuroinflammation in Alzheimer's disease[J].Int J Immunopathol Pharmacol,2012,25(2):345-353.
[4]
Korte M,Herrmann U,Zhang X,et al.The role of APP and APLP for synaptic transmission,plasticity,and network function:lessons from genetic mouse models[J].Exp Brain Res,2012,217(3-4):435-440.
[5]
Normando EM,Coxon KM,Guo L,et al.Focuson:amyloid beta[J].Exp Eye Res,2009,89(4):446-447.
[6]
Hartl D,Klatt S,Roch M,et al.Soluble alpha-APP(sAPPalpha)regulates CDK5 expression and activity in neurons[J].PLoSOne,2013,8(6):e65920.
[7]
Walsh DM,Selkoe DJ.A beta oligomers-adecade of discovery[J].JNeurochem,2007,101(5):1172-1184.
[8]
Sheng M,Sabatini BL,Sudhof TC.Synapses and Alzheimer's disease[J].Cold Spring Harb Perspect Biol,2012,4(5)pii:a005777
[9]
Hass C,Schlossmacher MG,Hung AY,et al.Amyloid beta-peptide is produced by cultured cells during normal metabolism[J].Nature,1992,359(6393):322-325.
[10]
Seubert P,Oltersdorf T,Lee MG,et al.Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide[J].Nature,1993,361(6409):260-263.
[11]
Murphy T,Yip A,Brayne C,et al.The BACE gene:genomic structure and candidate gene study in late-onset Alzheimer's disease[J].Neuroreport,2001,12(3):631-634.
[12]
Zohar O,Cavallaro S,D'Agata V,et al.Quantification and distribution of beta-secretase alternative splice variants in the rat and human brain[J].Brain Res Mol Brain Res,2003,115(1):63-68.
[13]
Turner RT 3rd,Loy JA,Nguyen C,et al.Specificity of memapsin 1 and its implications on the design of memapsin 2(beta-secretase)inhibitor selectivity[J].Biochemistry,2002,41(27):8742-8746.
[14]
Sun X,Wang Y,Qing H,et al.Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes[J].FASEB J,2005,19(7):739-749.
[15]
Sun X,He G,Song W.BACE2,as a novel APPtheta-secretase,is not responsible for thepathogenesis of Alzheimer's disease in Down syndrome[J].FASEB J,2006,20(9):1369-1376.
[16]
Liu X,Wang Z,Wu Y,et al.BACE2 degradation mediated by the macroautophagy-lysosome pathway[J].Eur J Neurosci,2013,37(12):1970-1977.
[17]
Bao XQ,Li N,Wang T,et al.FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation[J].PLoSOne,2013,8(11):e78033.
[18]
Liang B,Duan BY,Zhou XP,et al.Calpain activation promotes BACE1 expression,amyloid precursor protein processing,and amyloid plaque formation in a transgenic mouse model of Alzheimer disease[J].J Biol Chem,2010,285(36):27737-27744.
[19]
Yang LB,Lindholm K,Yan R,et al.Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease[J].Nat Med,2003,9(1):3-4.
[20]
Johnston JA,Liu WW,Todd SA,et al.Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease[J].Biochem Soc Trans,2005,33(Pt 5):1096-1100.
[21]
Holsinger RM,McLean CA,Beyreuther K,et al.Increased expression of the amyloid precursor beta-secretase in Alzheimer'sdisease[J].Ann Neurol,2002,51(6):783-786.
[22]
Vassar R,Bennett BD,Babu-Khan S,et al.Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE[J].Science,1999,286(5440):735-741.
[23]
Yan R,Bienkowski MJ,Shuck ME,et al.Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity[J].Nature,1999,402(6761):533-537.
[24]
Marcinkiewicz M,Seidah NG.Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouseand human brain[J].JNeurochem,2000,75(5):2133-2143.
[25]
Gatta LB,Albertini A,Ravid R,et al.Levels of beta-secretase BACE and alpha-secretase ADAM10 mRNAs in Alzheimer hippocampus[J].Neuroreport,2002,13(16):2031-2033.
[26]
Preece P,Virley DJ,Costandi M,et al.Beta-secretase(BACE)and GSK-3 levels in Alzheimer's disease[J].Brain Res Mol Brain Res,2003,116(1-2):155-158.
[27]
De Pietri Tonelli D,Mihailovich M,Di Cesare A,et al.Translational regulation of BACE-1 expression in neuronal and non-neuronal cells[J].Nucleic Acids Res,2004,32(5):1808-1817.
[28]
Singer O,Marr RA,Rockenstein E,et al.Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in atransgenic model[J].Nat Neurosci,2005,8(10):1343-1349.
[29]
Cai H,Wang Y,McCarthy D,et al.BACE1 is the major beta-secretase for generation of Abeta peptides by neurons[J].Nat Neurosci,2001,4(3):233-234.
[30]
Luo Y,Bolon B,Kahn S,et al.Mice deficient in BACE1,the Alzheimer's beta-secretase,have normal phenotype and abolished beta-amyloid generation[J].Nat Neurosci,2001,4(3):231-232.
[31]
Cole SL,Vassar R.The Alzheimer's disease beta-secretase enzyme,BACE1[J].Mol Neurodegener,2007,2(11):22.
[1] 王娟, 刘晔, 熊威, 蒋财磊, 贺燕, 叶青松. 间充质干细胞缓解阿尔茨海默病氧化应激的新思路[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 93-106.
[2] 王江波, 尹一鸣, 张冠群. 外周血生物标志物在阿尔茨海默病早期诊断中的价值[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 244-249.
[3] 李苒, 姜宇航, 陈泽浩, 何家恺, 闫珊珊, 鄢锦荣, 贾宝辉. 电针治疗阿尔茨海默病患者的先导性随机对照试验[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 218-224.
[4] 杨森, 阙玉梅, 丁莉, 王艺瑾, 侯庆宇. Hcy和AD7c-NTP在阿尔茨海默病诊断中的临床应用[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 208-212.
[5] 张萌, 喻中华. 阿尔茨海默病患者血清脂联素、Lp-PLA2、IL-17的表达及与认知功能的相关性分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(06): 358-363.
[6] 郭翃江, 符雪彩, 朱妍妍, 严之红, 王丽娜, 纪红. 基于影响因素的老年阿尔茨海默病认知功能障碍预测模型构建及电子化认知康复训练的应用价值[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(03): 156-161.
[7] 李敏, 刘云. 血清SAA、sNFL水平对老年阿尔茨海默病的预测价值分析[J]. 中华脑科疾病与康复杂志(电子版), 2022, 12(03): 157-161.
[8] 于伟伟, 张国高, 吴军, 胡俊, 黄一宁, 徐晶. 线粒体相关内质网膜相关线粒体功能障碍在阿尔茨海默病中的研究进展[J]. 中华临床医师杂志(电子版), 2024, 18(02): 223-230.
[9] 刘倩, 李鑫, 刘欣, 苑金香. 铁死亡在阿尔茨海默病发病机制中的研究进展[J]. 中华诊断学电子杂志, 2022, 10(03): 211-215.
[10] 陆静, 钟为慧, 赵杰, 曾玲晖. 髓系细胞触发受体2在β淀粉样蛋白病理致阿尔茨海默病中的作用机制[J]. 中华老年病研究电子杂志, 2024, 11(01): 51-56.
[11] 赵晓晓, 邱嘉婷, 张懿姝, 张蓉, 张棚, 刘晓蕾. 丁苯酞在各类型认知障碍治疗中的应用研究进展[J]. 中华脑血管病杂志(电子版), 2024, 18(01): 19-26.
[12] 曾德阳, 董贺千禧, 陶凉, 肖红艳, 曾燕, 鄢华. 中年心血管危险因素增加阿尔茨海默病相关痴呆的流行病学和机制研究进展[J]. 中华脑血管病杂志(电子版), 2024, 18(01): 6-13.
[13] 刘天姿, 王宝军. Toll样受体4在阿尔茨海默病中的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 404-409.
[14] 夏禹, 刘寒, 朱瑞. 阿尔茨海默病及相关认知障碍疾病与早老素2基因相关性的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(03): 290-293.
[15] 宋蕾, 吴寒, 侯双兴, 楼菁菁, 刘兴党. 关于阿尔茨海默病中视网膜和视神经及相关物质的研究进展[J]. 中华脑血管病杂志(电子版), 2022, 16(05): 351-355.
阅读次数
全文


摘要